MCL Literature Feed

Mantle cell lymphoma can present with prolymphocytic morphology, a diagnostic pitfall mimicking other lymphoproliferative disorders that requires ancillary testing like cyclin D1 IHC for accurate diagnosis.

This case of clonally-related composite DLBCL and CD5-negative MCL highlights a rare diagnostic challenge, emphasizing the need for comprehensive IHC panels to avoid misdiagnosing transformed lymphoma.

Ibrutinib monotherapy rapidly resolved bilateral intraocular MCL recurrence presenting as pseudo-uveitis and glaucoma, demonstrating its efficacy in this rare CNS sanctuary site relapse.

Genomic analysis of a single MCL patient identified specific mechanisms of resistance to PD-L1 blockade, providing crucial insights into why checkpoint inhibitors are often ineffective in this lymphoma.

This review details the evolution of BTK inhibitors from discovery to clinical use in MCL, covering first-generation agents like ibrutinib and newer agents designed to overcome resistance.

This review summarizes the evolution of BTK inhibitors, highlighting how next-generation agents like pirtobrutinib offer improved selectivity, reduced toxicity, and options to overcome resistance in MCL.

This study validates a method using electronic health records to define real-world progression in MCL, providing a scalable endpoint that correlates strongly with overall survival for evidence generation.

A rare case of co-existing CNS DLBCL and systemic MCL was successfully treated with a multi-modal approach including chemotherapy, ibrutinib bridging, and autologous transplant, achieving 3-year remission.

In high-risk, relapsed/refractory MCL, real-world data shows BTKi plus venetoclax is highly effective, with no added survival benefit from an anti-CD20 monoclonal antibody.

This review summarizes the expanding role of T-cell directing immunotherapies, like bispecifics and CAR-T, in treating relapsed/refractory NHL, providing a framework for their application in MCL.

In a retrospective, mixed-histology study including four MCL patients, splenectomy plus chemotherapy improved survival for aggressive lymphomas presenting with primary splenic involvement, suggesting a potential therapeutic role.

In a prospective cohort of primary GI lymphomas including MCL, routine endoscopic surveillance significantly improved overall survival by detecting relapse early, supporting its role in post-treatment management.

This preclinical study reveals bortezomib, unlike carfilzomib, induces unique multi-organelle stress in endothelial cells, providing a specific mechanism for its cardiovascular toxicity relevant to MCL patients.

Integrated genomic and transcriptomic profiling identifies novel molecular subsets of MCL that predict patient outcomes, paving the way for risk-stratified therapy.

The protein TRIM24 regulates autophagy-mediated resistance to the proteasome inhibitor bortezomib, offering a potential new therapeutic target to overcome drug resistance in relapsed/refractory MCL.

A new CAR-T hematotoxicity score developed for B-ALL, which replaces ferritin with bone marrow burden, highlights the need to refine existing models like CAR-HT used in MCL for disease-specific prediction.

This retrospective Chinese study validates POD24 (progression within 24 months) as a powerful negative prognostic marker and incorporates it into a new model to better risk-stratify relapsed patients.

Alternating R-DA-EDOCH/R-DHAP induction for young, newly diagnosed MCL patients achieved an 89% complete remission rate and high MRD negativity, offering a potent new frontline intensive chemotherapy option.

A case of Candida albicans meningoencephalitis in an MCL patient highlights the diagnostic challenge of CNS symptoms, underscoring the need to consider opportunistic fungal infections beyond CNS relapse.

In a small real-world study of 38 relapsed/refractory MCL patients, zanubrutinib was associated with fewer select adverse events like hypertension and hemorrhage compared to acalabrutinib.

This case series identifies a rare intrasinusoidal bone marrow involvement pattern in MCL, highlighting a key diagnostic pitfall for pathologists and expanding the disease's recognized histopathological spectrum.

Combining acalabrutinib with bendamustine-rituximab is safe and highly active, achieving a 78% complete response rate and unreached median progression-free survival at 47.6 months in treatment-naive mantle cell lymphoma.

In previously untreated, transplant-ineligible MCL, achieving MRD-negativity after bendamustine-obinutuzumab induction allows for the safe omission of maintenance therapy without worsening progression-free survival.

This review outlines emerging therapeutic strategies, including non-covalent BTKis, CAR-T, and bispecifics, for managing the clinically challenging population of MCL patients relapsing after covalent BTK inhibitors.

This review highlights using geriatric assessments to guide therapy selection and proactively manage toxicities in older MCL patients, aiming to optimize outcomes and avoid over- or undertreatment.

A Mendelian randomization study suggests a causal link between higher abundance of the gut bacterium Holdemania filiformis and a significantly reduced risk of developing mantle cell lymphoma.

This review summarizes how BTKi integration into frontline therapy (TRIANGLE trial) challenges the role of transplant, while CAR-T cells are established as the best option after BTKi failure.

In mantle cell lymphoma, MRD assessment is most predictive of survival after four induction cycles, while rapid clearance within two cycles offers no prognostic benefit, guiding risk stratification.

In a real-world US analysis, relapsed/refractory MCL patients receiving CAR-T had longer treatment-free intervals and lower subsequent healthcare costs compared to standard therapies, supporting its earlier use.

Brexu-cel CAR-T therapy induced a durable 15-month complete remission in a rapidly progressing, relapsed/refractory MCL patient post-BTKi, highlighting its efficacy despite manageable rare cardiovascular toxicities.